• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
GAO Tianshu,HU Weifeng,XIAO Yuxiao,SU Xiaoyu,LI Jiaqi,JIA Yuhan,WANG Xing,CHEN Zhen.Research progress of xanthine oxidase inhibitors[J].Journal Of Pharmaceutical Research,2022,41(9):605-610[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2580times   Download 1939次 QR Code for this article
Scan with your phone!
黄嘌呤氧化酶抑制剂的研究进展
高天舒1,胡伟凤2,肖愉箫1,苏晓语1,李嘉琦1,贾昱晗1,王星1,3,陈真1
Font:Larger+|Default|Smaller-
(1.中国药科大学药学院,江苏 南京 211198;2.中国药科大学基础医学与临床药学学院,江苏 南京 211198;3.江苏文锂生物科技有限责任公司,江苏 句容 212415)
摘要:
黄嘌呤氧化还原酶(Xanthine oxidoreductase,XOD)是一种高度通用的黄素酶,在不同物种之间以及生物各种组织中普遍存在。痛风是由于体内尿酸代谢障碍,导致尿酸水平过高,影响机体的正常运行。抑制黄嘌呤氧化还原酶可以降低尿酸水平,发挥抗高尿酸的作用。现如今临床上用于治疗痛风、高尿酸血症最有效的药物还是黄嘌呤氧化还原酶抑制剂。本文归纳了黄嘌呤氧化还原酶抑制剂的药理作用和临床应用,并对近年来已经上市和处于开发阶段的黄嘌呤氧化还原酶抑制剂进行总结,综述了黄嘌呤氧化还原酶抑制剂的最新进展。
关键词:  黄嘌呤氧化酶  尿酸  黄嘌呤氧化酶抑制剂
DOI:10.13506/j.cnki.jpr.2022.09.009
基金项目:江苏省自然科学基金资助项目(No.BK20180547);2019年句容“福地英才”计划项目(No.201913);中国药科大学国家级大学生创新创业训练计划项目成果(No.202010316035S)
Publication Date:September 25, 2022
Research progress of xanthine oxidase inhibitors
GAO Tianshu1,HU Weifeng2,XIAO Yuxiao1,SU Xiaoyu1,LI Jiaqi1,JIA Yuhan1,WANG Xing1,3,CHEN Zhen1
(1.School of Pharmacy, China Pharmaceutical University,Nanjing 211198,China;2.School of Basic Medicine and Clinical Pharmacy,China Pharmaceutical University, Nanjing 211198,China;3.Jiangsu Wenli Biotechnology Co., Ltd., Jurong 212415,China)
Abstract:
Xanthine oxidoreductase (XOD) is a highly versatile flavinase, which is ubiquitous in different species and tissues. Gout is due to the metabolic disorder of uric acid in the body, which leads to the high level of uric acid and affects the normal operation of the body. Inhibition of XOD can reduce the level of uric acid and play the role of anti hyperuricemia. Nowadays, the most effective drug for the treatment of gout and hyperuricemia is XOD inhibitor. This paper summarized the pharmacological effects and clinical applications of XOD inhibitors, and summarized the XOD inhibitors that have been on the market and in the development stage in recent years, and reviewed the latest progress of XOD inhibitors.
Key words:  Xanthine oxidase  Uric acid  Xanthine oxidase inhibitor
Today's Visits:485    Total Visits:2383197
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.